メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
日本大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
専門家に連絡
Scopus著者プロファイル
増崎 亮太
助教
医学部
h-index
3414
被引用数
25
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2007
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(93)
類似のプロファイル
(6)
フィンガープリント
Ryota Masuzakiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Patient
79%
Chronic Hepatitis C
53%
Inpatient
43%
Liver
40%
Transient Elastography
39%
Radiofrequency Ablation
29%
Therapeutic Procedure
27%
Surveillance
27%
Hepatitis C Virus
23%
Development
22%
Risk Assessment
19%
Perfluorobutane
19%
Measurement
17%
Antivirus Agent
16%
Screening
15%
Fibrosis
15%
Hepatitis C
15%
Liver Fibrosis
15%
Mortality
13%
Chronic Hepatitis
13%
Liver Disease
12%
Liver Biopsy
12%
Liver Cirrhosis
12%
Serum
11%
Lesion
11%
Outpatient
11%
Neoplasm
11%
Echography
11%
Obesity
11%
Alanine Aminotransferase
10%
Aging
9%
Regeneration
9%
Adult
9%
Scar Formation
9%
Decompensated Liver Cirrhosis
9%
Adiponectin
9%
Mechanism of Action
9%
Regorafenib
9%
Lenvatinib
9%
Hepatoma Cell
9%
Nonalcoholic Fatty Liver
9%
Isoenzyme
9%
COVID-19
9%
microRNA 221
9%
Dicer
9%
Cell Activity
9%
Integrin
9%
Liver Development
9%
Image Analysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
56%
Recurrent Disease
24%
Hepatitis C Virus
23%
Chronic Liver Disease
13%
Interferon
12%
Liver Cancer
12%
Chronic Hepatitis
12%
Liver Cirrhosis
10%
Adiponectin
9%
Grazoprevir
9%
Elbasvir
9%
Fat
9%
Regorafenib
9%
Autotaxin
9%
microRNA 221
9%
Dicer
9%
Nonalcoholic Fatty Liver
9%
Hepatitis B Virus
9%
Liver Carcinogenesis
9%
Interleukin 6
9%
Hepatitis
9%
Infection
9%
Hepatitis A Virus
9%
Diethylnitrosamine
9%
Mitogen Activated Protein Kinase Kinase 3
9%
Virus DNA
9%
Suppressor of Cytokine Signaling 2
9%
Antiviral Therapy
9%
Tolvaptan
9%
Kidney Polycystic Disease
9%
Hepatitis C Virus Genotype 4
9%
Glecaprevir
9%
Cell Culture
9%
Pibrentasvir
9%
Liver Fibrosis
9%
Alpha2a Interferon
9%
Ribavirin
9%
Lymphadenopathy
9%
Hepatitis C Virus Genotype 1
9%
Peginterferon
9%
Fibrosis
9%
Peginterferon Alpha
9%
Fluorouracil
9%
Perflubutane
9%
Nicotinamide
9%
Bone Morphogenetic Protein
9%
Drug Screening
9%
Bone Morphogenetic Protein Receptor 1A
9%
Sorafenib
6%
Peginterferon Alpha2a
6%
Biochemistry, Genetics and Molecular Biology
Rigidity
29%
Interferon
21%
Elastography
21%
Hepatitis C Virus
16%
Ultrasonography
14%
Development
12%
Alpha-Fetoprotein
10%
Adiponectin
9%
Regorafenib
9%
Radiofrequency
9%
Autotaxin
9%
Matrix Metalloproteinase
9%
Tissue Inhibitor of Metalloproteinase
9%
Creatine Kinase
9%
Isoenzyme
9%
Ultrasound
9%
Thrombospondin
9%
Disintegrin
9%
Metalloproteinase
9%
Cell Activity
9%
Interleukin 6
9%
Sex Difference
9%
Training
9%
Cytokine
9%
Hepatitis A Virus
9%
Liver Regeneration
9%
Metabolic Balance
9%
Ribavirin
9%
Hepatitis C Virus Genotype 1
9%
Mitogen-Activated Protein Kinase
9%
Tumor Necrosis Factor Alpha
9%
Single-Cell Analysis
9%
Cytometry
9%
Nicotinamide
9%
Drug Screening
9%
Incidence
8%
Hepatocyte
8%
Time
7%
Classification
7%
Virus Load
6%
Screening
6%
Survival
6%
Tumor Marker
5%
Sample
5%
Cancer Staging
5%
Tumor Volume
5%
